• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Research Summaries

Does Maternal COVID-19 Vaccination Protect Against Infant Hospitalization Due to COVID?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Halasa et al. (CDC MMWR, 2022) assessed the effectiveness of maternal completion of a 2-dose mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization in infants

METHODS:

  • Test-negative, case-control study
    • Real-world evaluation at 20 US pediatric hospitals during a period of Delta and Omicron variant circulation
  • Participants
    • Infants aged <6 months admitted outside of their birth hospitalization to a pediatric hospital during July, 2021 to January, 2022
      • Case infants had a positive COVID-19 test
      • Control infants had a negative COVID-19 test
  • Exposure
    • Maternal vaccination ≥14 days before delivery
      • Defined as completion of a 2-dose series of either Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine
  • Study design
    • Control-infants were matched to case-infants by site and were hospitalized within 3 to 4 weeks of a case-infant’s admission date
    • In a secondary analysis, effectiveness of maternal receipt of the second dose of COVID-19 vaccination early in pregnancy (within the first 20 weeks) and late in pregnancy (21 weeks through 14 days before delivery) was assessed
  • Primary outcome
    • Vaccine effectiveness (VE) of maternal vaccination against infant COVID-19 hospitalization

RESULTS:

  • Case infants: 176 | Control infants: 203
    • Median age 2 months
    • Had at least one underlying medical condition: 21%
    • Born premature (<37 weeks): 22%
  • Effectiveness of maternal vaccination during pregnancy against COVID-19 hospitalization in infants aged <6 months
    • VE: 61% (95% CI, 31 to 78%)
  • Effectiveness of a completed 2-dose COVID-19 vaccination series early in pregnancy (first 20 weeks)
    • VE: 32% (95% CI, –43% to 68%)
  • Effectiveness of vaccine completion late in pregnancy (21 weeks through 14 days before delivery)
    • VE: 80% (95% CI, 55 to 91%)

CONCLUSION:

  • Maternal COVID-19 immunization appears to provide protection to infants through passive transplacental antibody transfer
  • Maternal vaccination had a VE of 61% for preventing COVID-19 hospitalization in infants
  • The authors state

Overall, these findings indicate that maternal vaccination during pregnancy might help protect against COVID-19 hospitalization among infants aged <6 months

Learn More – Primary Sources:

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Research Summaries Posts

Related ObG Topics:

More Evidence that Maternal Influenza Vaccination is Safe and Effective
Latest Data on Transplacental Antibody Transfer Following COVID-19 Vaccination
Does COVID-19 Vaccination in Breastfeeding Women Produce Detectable Levels of Antibodies in Breast Milk?
Vaccines in Pregnant and Lactating Women: Is Immune Response Similar to that of Non-Pregnant Patients?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site